In the TME, receptors of PD-L1 and CD80 expressed by tumor cells or tumor-related immune cells can interact with PD-1 and CTLA-4 expressed by CD8 T cells, respectively, to impair CD8 T cell function [13, 14]. This evidence concerns the gene PDCD1 and neoplasm.